Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (281)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00379080 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00792012 | A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma | completed | Phase 1 | 37 | University of Colorado, DenverOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT01250470 | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT01238237 | Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA | completed | Phase 1 | 15 | Northwell HealthOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT00085540 | FR901228 in Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 2, 2017 | clinicaltrials |
| NCT01308684 | A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma | completed | Phase 1 | 22 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT01547546 | A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma | completed | Phase 1 | 29 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT02104882 | INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study | completed | Phase 1 / Phase 2 | 12 | Universitätsmedizin MannheimOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01588769 | A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients(ALECSAT-GBM) | completed | Phase 1 | 23 | CytoVac A/SINDUSTRY | 1 | Jun 6, 2016 | clinicaltrials |
| NCT01833273 | Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA(DESSTINI_A) | completed | Phase 1 | 13 | Stony Brook UniversityOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01144247 | Cellular Immunotherapy Study for Brain Cancer(alloCTL) | completed | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT01435395 | Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme | completed | Phase 1 | 12 | Emory UniversityOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT01475006 | AMG 595 First-in-Human in Recurrent Gliomas | completed | Phase 1 | 32 | AmgenINDUSTRY | 2 | Apr 15, 2016 | clinicaltrials |
| NCT00085254 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 112 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00250211 | Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide | completed | Phase 1 / Phase 2 | 26 | AHS Cancer Control AlbertaOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT00301418 | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma | completed | Phase 1 / Phase 2 | 11 | Northwell HealthOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT00116376 | Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) | completed | Phase 1 / Phase 2 | 64 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 10, 2015 | clinicaltrials |
| NCT02092038 | Preoperative Chemoradiation for Glioblastoma | completed | Phase 1 | 1 | Tampa General HospitalOTHER | 1 | Nov 10, 2015 | clinicaltrials |
| NCT00846456 | Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma | completed | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 0 | Oct 20, 2015 | clinicaltrials |
| NCT01119599 | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2015 | clinicaltrials |
| NCT01111097 | Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors | completed | Phase 1 | 15 | University of FloridaOTHER | 1 | Sep 22, 2015 | clinicaltrials |
| NCT00087451 | Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) | completed | Phase 1 | 11 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00112736 | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2015 | clinicaltrials |
| NCT00821080 | Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma | completed | Phase 1 | 33 | Massachusetts General HospitalOTHER | 1 | May 1, 2015 | clinicaltrials |
| NCT00968240 | Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) | completed | Phase 1 | 30 | Northwell HealthOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00049387 | Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00979862 | Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00694837 | Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma | completed | Phase 1 | 6 | Maastricht Radiation OncologyOTHER | 1 | Apr 10, 2015 | clinicaltrials |
| NCT01582516 | Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00179907 | A Phase I/II Study of the Photon Radiosurgery System | completed | Phase 1 / Phase 2 | 35 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 2, 2015 | clinicaltrials |
| NCT00734682 | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 34 | University of California, San FranciscoOTHER | 1 | Jan 7, 2015 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT02227901 | Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00024570 | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 60 | INSYS Therapeutics IncINDUSTRY | 1 | Nov 14, 2014 | clinicaltrials |
| NCT00884416 | Sorafenib in Newly Diagnosed High Grade Glioma | completed | Phase 1 | 17 | University Hospital, GenevaOTHER | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00576641 | Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma | completed | Phase 1 | 22 | Cedars-Sinai Medical CenterOTHER | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00960492 | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma | completed | Phase 1 | 26 | ExelixisINDUSTRY | 1 | Sep 22, 2014 | clinicaltrials |
| NCT00611728 | Ph I SU011248 + Irinotecan in Treatment of Pts w MG | completed | Phase 1 | 25 | Duke UniversityOTHER | 1 | Jul 21, 2014 | clinicaltrials |
| NCT00609999 | Ph I Dasatinib + Erlotinib in Recurrent MG | completed | Phase 1 | 47 | Duke UniversityOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00612989 | Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | completed | Phase 1 | 42 | Duke UniversityOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00093613 | Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00650923 | Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00042991 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00575146 | Ketogenic Diet for Recurrent Glioblastoma(ERGO) | completed | Phase 1 | 20 | University Hospital TuebingenOTHER | 1 | May 2, 2014 | clinicaltrials |
| NCT00610571 | Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | completed | Phase 1 | 62 | Katy PetersOTHER | 1 | Oct 25, 2013 | clinicaltrials |
| NCT00385853 | PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs | completed | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Oct 21, 2013 | clinicaltrials |
| NCT00762255 | A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 25, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Apr 7, 2017source: clinicaltrials